Answers are grounded in this paper and cite their sources.
In 2017, the Food and Drug Administration approved 2 medications for sickle cell anemia (SCA): hydroxyurea for children and l-glutamine for children and adults. The approval of hydroxyurea was long overdue, but the approval of l-glutamine was a surprise to many. Any effective new treatment for SCA is a welcome advance, but there are few published studies of l-glutamine as a specific treatment for SCA. Accordingly, there are many unanswered questions about its efficacy, safety, and role in current therapy.
No takes yet. Share an insight, caveat, or question.
Charles T. Quinn (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: